Check out today’s featured companies who have recently completed an M&A deal, and be sure to check out the full list of past healthcare IT M&A.
Experity Acquires Exdion Healthcare to Accelerate AI-Driven Revenue Cycle Management Automation for On-Demand Care
Urgent Care Operators can Achieve Faster Reimbursement, Cleaner Claims, and Minimal Denials with Limited Human Intervention Using this AI-Driven Platform
Experity, the market-leading on-demand healthcare technology platform trusted by nearly half of all urgent care clinics in the U.S., today announced it has acquired Exdion Healthcare, an AI-driven SaaS software and services company specializing in the patient chart-to-cash lifecycle, including coding, billing, compliance, and revenue cycle automation.
The acquisition advances Experity’s strategy to unify clinical, operational, and financial workflows with AI, helping urgent care operators to accelerate reimbursement, reduce manual work, and improve financial performance at scale.
“This marks a decisive shift from labor-intensive RCM to AI-driven workflow optimization,” said Jason McNeil, EVP of RCM at Experity. “Over the past several years, we’ve helped clients collect billions in revenue. Together with Exdion, we’re positioned to significantly scale that impact, while reducing administrative burden, minimizing claim errors and denials, improving payment velocity, and closing gaps that lead to lost revenue.”
Exdion’s platform currently processes the vast majority of its patient visits autonomously. Its AI-driven model combines proprietary machine learning and domain-trained data workflows to deliver high accuracy and efficiency, while limiting the need for manual intervention.
“The combined capabilities of Experity and Exdion deliver measurable, transformative results,” said Lohith Reddy, President at Exdion…
Full release here, originally announced July 1st, 2026.
ResMed to Sell Software Business MatrixCare for $490 Million
ResMed, opens new tab said on Tuesday it would sell its software business, MatrixCare, to private equity firm Frazier Healthcare Partners for $490 million in cash, as the health technology company sharpens its focus on sleep, breathing and home-based care.
ResMed, which makes devices to manage sleep apnea, said it plans to use the net proceeds to return capital to shareholders, including through an accelerated share repurchase program, and for general corporate purposes…
Full release here, originally announced July 7th, 2026.
No comments:
Post a Comment